Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

ctDNA, Total Neoadjuvant Therapy, and TAS-102 Signal a Shift in CRC Management

March 12th 2021

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.

Dr. Kazmi on Choosing Among Regorafenib and TAS-102 in Metastatic CRC

March 11th 2021

Syed Kazmi, MD, discusses choosing among regorafenib and TAS-102 in the treatment of patients with metastatic colorectal cancer.

ctDNA and Molecular Alterations Among Important Treatment Considerations in CRC

March 11th 2021

Atrayee Basu-Mallick, MD, discusses the emerging role of ctDNA as a predictive biomarker in early-stage CRC and the growing importance of molecular testing in the advanced-stage setting.

Dr. Basu-Mallick on Selecting Frontline HER2-Directed Therapy in CRC

March 10th 2021

Atrayee Basu-Mallick, MD, discusses factors to consider when selecting a frontline HER2-directed treatment regimen for patients with colorectal cancer.

Ciombor Cites Challenges in Optimizing Care for Locally Advanced Rectal Cancer

March 10th 2021

Determining the appropriate sequencing for chemotherapy and radiation in patients with locally advanced rectal cancer is important and may depend on whether the goal of therapy is nonoperative management.

Dr. Philip on the Emerging Role of ctDNA in CRC

March 9th 2021

Tony Philip, MD, discusses the emerging role of circulating tumor DNA in colorectal cancer.

Expert Panel Considers Clinical Scenarios With Data Gaps in GI Malignancies

March 8th 2021

Cathy Eng, MD, FACP, FASCO, and Jordan D. Berlin, MD discuss pressing questions in hepatocellular carcinoma, colorectal cancer, gastric cancer, neuroendocrine tumors, and pancreatic cancer.

Dr. Grothey on the Potential Utility of TAS-102/Bevacizumab in Metastatic CRC

March 8th 2021

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Dr. Basu-Mallick on Ongoing Research With ctDNA in CRC

March 5th 2021

Atrayee Basu-Mallick, MD, discusses the role of circulating tumor DNA in patients with colorectal cancer.

Dr. Bekaii-Saab on the Toxicity Differences Between Regorafenib and TAS-102 in CRC

March 4th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Philip on the Efficacy of TAS-102 in mCRC

March 4th 2021

Tony Philip, MD, discusses the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer who are ineligible for intensive treatment.

Dr. Grothey on Dosing Strategies With Regorafenib in CRC

March 3rd 2021

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Kazmi on Differences Between Left- Versus Right-Sided CRC Tumors

February 23rd 2021

Syed Kazmi, MD, discusses differences between left- and right-sided tumors in patients with colorectal cancer.

ASCO GI 2021: MRD Detection With ctDNA From Assays

February 22nd 2021

Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.

ASCO GI 2021: Circulating Tumor DNA Analysis Data

February 22nd 2021

An overview of data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal) 2021 Annual Meeting, regarding the circulating tumor DNA for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment of patients with colorectal cancer (CRC).

ctDNA Monitorization Length and Clinical Experience

February 22nd 2021

Experts in the management of colorectal cancer (CRC) consider how long patients with early stage disease should receive ctDNA (circulating tumor DNA) monitorization, and provide insight into their personal experience using ctDNA testing.

Cologuard mt-sDNA Test Could Provide a Noninvasive Screening Option for CRC

February 19th 2021

February 19, 2021 - Multitarget stool DNA test Cologuard could present a potential noninvasive screening method for colorectal cancer, as it has demonstrated high specificity among average-risk patients aged 45 to 49 years.

Dr. Dasari on the Rationale for the FRESCO-2 Trial With Fruquintinib in mCRC

February 19th 2021

Nageshwara Arvind Dasari, MD, discusses the rationale to evaluate fruquintinib in the ongoing, phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer.

Dr. Wainberg on the Need for Chemotherapy-Free Options in CRC

February 18th 2021

Zev A. Wainberg, MD, discusses the need to develop chemotherapy-free options in colorectal cancer.

Dr. Ciombor on the Efficacy of Preoperative Chemoradiation in Rectal Cancer

February 17th 2021

Kristen K. Ciombor, MD, MSCI, discusses responses achieved with preoperative chemoradiation in patients with rectal cancer.